Inhibition of Mycobacterium tuberculosis Dethiobiotin Synthase (MtDTBS): Toward Next-Generation Antituberculosis Agents.
Nicholas C SchumannKwang Jun LeeAndrew P ThompsonWanisa SalaemaeJordan L PederickThomas AveryBirgit I GaiserJames Hodgkinson-BeanGrant W BookerSteven W PolyakJohn B BruningKate L WegenerAndrew D AbellPublished in: ACS chemical biology (2021)
Mycobacterium tuberculosis dethiobiotin synthase (MtDTBS) is a crucial enzyme involved in the biosynthesis of biotin in the causative agent of tuberculosis, M. tuberculosis. Here, we report a binder of MtDTBS, cyclopentylacetic acid 2 (KD = 3.4 ± 0.4 mM), identified via in silico screening. X-ray crystallography showed that 2 binds in the 7,8-diaminopelargonic acid (DAPA) pocket of MtDTBS. Appending an acidic group to the para-position of the aromatic ring of the scaffold revealed compounds 4c and 4d as more potent binders, with KD = 19 ± 5 and 17 ± 1 μM, respectively. Further optimization identified tetrazole 7a as a particularly potent binder (KD = 57 ± 5 nM) and inhibitor (Ki = 5 ± 1 μM) of MtDTBS. Our findings highlight the first reported inhibitors of MtDTBS and serve as a platform for the further development of potent inhibitors and novel therapeutics for the treatment of tuberculosis.
Keyphrases
- mycobacterium tuberculosis
- pulmonary tuberculosis
- anti inflammatory
- high resolution
- photodynamic therapy
- small molecule
- squamous cell carcinoma
- emergency department
- molecular docking
- single cell
- magnetic resonance imaging
- ionic liquid
- neoadjuvant chemotherapy
- replacement therapy
- human immunodeficiency virus
- magnetic resonance
- radiation therapy
- cell wall
- mass spectrometry
- lymph node